Autopsy report · NCT05172141

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

“Due to the company's development strategy adjustment, Innovant Biologics decided not to continue this study after consultation with investigators.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 222 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Conditions

COVID-19

Interventions

IBI314(low dose); IBI314(high dose); IBI314(medium dose); Placebo

Participants

222

Sites

1

Countries

China

Trials that died the same way

• A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
  “Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators.” (80% match in meaning)
• MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
  “Drug provider decided not to move forward with the study.” (61% match in meaning)
• A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
  “The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.” (61% match in meaning)
• To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy
  “The investigators decided not to proceed with this study” (61% match in meaning)
• A Coach-Guided Online Acceptance and Commitment Therapy (ACT) Intervention for Stroke Survivors
  “The research team decided not to implement this study.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.